Clinical Trial Detail

NCT ID NCT03173248
Title Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Azacitidine + Ivosidenib

Ivosidenib

Age Groups: adult senior

Additional content available in CKB BOOST